Scopa James Paul
- SEC CIK
- 0001356950
No open-market purchases or sales filed in the past year.
Current role at each company
- ALGS Aligos Therapeutics, Inc.Directoras of Jun 29, 2026
- ADVM Adverum Biotechnologies, Inc.Directoras of Dec 10, 2025
- DICE DICE Therapeutics, Inc.Directoras of Aug 9, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Scopa James Paul as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ADVM Adverum Biotechnologies, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 9, 2024 (view filing) | Feb 7 | 2 days | Scopa James PaulDirector | PPurchase | +100.0K | $1.35 | +$135.0K | New position100.0K after | |
| Nov 17, 2021 (view filing) | Nov 15 | 2 days | Scopa James PaulDirector | SSale | −50.0K | $2.18 | −$109.0K | −93.7%3.33K after |
DICE DICE Therapeutics, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 21, 2023 (view filing) | Mar 17 | 4 days | Scopa James PaulDirector | SSale | −10.0K | $29.05 | −$290.5K | −29.7%23.7K after | |
| Sep 16, 2021 (view filing) | Sep 15 | 1 day | Scopa James PaulDirector | PPurchase | +6.00K | $17.00 | +$102.0K | +12.0%55.8K after |